Cancer-related Venous Thromboembolic Disease - Cohort Study

Launched by UNIVERSITY HOSPITAL, BREST · Apr 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called venous thromboembolic disease (VTE), which is when blood clots form in the veins. This condition is particularly concerning for patients with cancer, as they have a higher risk of developing VTE, which can lead to serious complications like pulmonary embolism (a blockage in the lungs). The goal of this study is to better understand the relationship between cancer and blood clots, as well as to identify the risks and treatment options for patients facing this challenge.

To participate in this study, individuals must be 18 years or older and currently have active cancer or be receiving treatment for it. They should also have a documented case of VTE that occurred within the last two years. Participants will be asked to sign a consent form agreeing to take part in the study. It’s important to note that individuals who are under 18, unable to give consent, or have a life expectancy of less than six months will not be eligible. This study aims to gather valuable information that could lead to better management of blood clots in cancer patients, helping to improve their overall care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 years and more.
• • Patients with active cancer or requiring cancer treatment at the time of their VTE episode
• • Patients with documented VTE less than 2 years old
• • Patients affiliated to the social security system
• • Patient who has signed a written informed consent
• Exclusion Criteria:
• • Patient under 18
• • Refusal to participate
• • Incapacity to consent to the study
• • Patient under guardianship
• • Incapacity to communicate (comprehension disorder)
• • Life expectancy of less than 6 months